Here's Why You Should Hold On To Insulet (PODD) Stock Now
Zacks Investment Research | Dec 30, 2019 10:53PM ET
Insulet Corporation (NASDAQ:PODD) has been progressing well with respect to its four-pronged strategy and already seems on track to achieve revenues of $1 billion by 2021. The four key initiatives are expanding Omnipod’s market access, executing on its innovation roadmap, building the U.S. manufacturing facility and implementing its plan to sell directly in Europe. However, a tough competitive landscape and macroeconomic uncertainty are likely to offset the positives to some extent.
This $10.66-billion worth commercial developer of insulin treatment expects a skyrocketing earnings growth rate of 263.2% for next year. Also, the company has a trailing four-quarter negative earnings surprise of 145.8%, on average.
Let’s delve deeper into the factors that substantiate the company’s Zacks Rank #3 (Hold).
Advancement of U.S. Manufacturing Facility: Management seems to be particularly upbeat about the manufacturing unit in Acton, MA. The company is currently in process of installing its second U.S. manufacturing line with production of saleable items expected by mid-2020.
Insulet Corporation Price
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.